TSCA's Fee Authority Renewal Fight: What Chemical Regulation Reform Could Mean for Testing Costs
TSCA's Fee Authority Renewal Fight: What Chemical Regulation Reform Could Mean for Testing Costs
The U.S. Environmental Protection Agency’s authority to collect fees under the Toxic Substances Control Act (TSCA) has become the focal point of a broader debate over chemical regulation. That authority was scheduled to expire at the end of fiscal year 2026; a continuing resolution has extended it only until December 11, 2026. Behind the short-term extension lies a larger contest: whether Congress will simply renew the fee program or use the deadline to reopen wider TSCA reforms. For chemical manufacturers and importers the stakes include the cost of new-chemical notifications, the shared burden of EPA-initiated risk evaluations, and the potential expense of testing orders—costs that already run into tens of thousands of dollars per submission and, in the case of major risk evaluations, into the millions.
Fees under TSCA Section 26(b) partially cover EPA’s expenses for reviewing new chemicals and significant new uses (Section 5), conducting risk evaluations of existing chemicals (Section 6), overseeing testing (Section 4), and processing confidential-business-information claims (Section 14). How those fees are set, who pays them, and whether the underlying statutory timelines and data requirements change will directly affect testing and compliance budgets across the industry.
Why Fee Authority Matters
TSCA fees were designed to shift a portion of program costs from general appropriations onto the companies that submit notices or manufacture chemicals subject to evaluation. In practice, collections have varied widely year to year—sometimes only a few million dollars, occasionally far higher when a cluster of risk evaluations is initiated. EPA has estimated total annual program costs for the relevant TSCA activities in the range of $140 million-plus; fee receipts cover only a fraction of that total. The balance still depends on congressional appropriations.
Because fee levels are set by rule within statutory limits, the size of individual invoices is material. A new-chemical notice can carry a fee on the order of $37,000 for a standard submitter (lower for qualifying small businesses). An EPA-initiated risk evaluation of an existing chemical has been structured so that the manufacturers and importers of that substance share a total fee in the low millions of dollars. Testing-related fees under Section 4 add further line items when EPA issues test orders. Any reauthorization that alters the fee formula, the cost-allocation rules, or the underlying data requirements will therefore change the direct compliance cost of bringing new molecules to market or defending existing ones.
The Renewal Fight and Broader Reform Pressure
Industry groups and some members of Congress have linked fee reauthorization to complaints about review delays, the volume of data requested, and the overall pace of both new-chemical and existing-chemical programs. Environmental and public-health organizations counter that the fee deadline is being used as a “Trojan horse” to weaken core TSCA protections and that simple appropriations language could extend the fee authority without reopening the statute. Draft legislation and committee discussion drafts circulating in 2026 have explored multi-year reauthorization alongside potential changes to review timelines, the treatment of new chemicals, and the conduct of risk evaluations.
The outcome is still unsettled. A clean, short- or medium-term extension would largely preserve the current fee structure and testing framework. A broader bill could adjust fee ceilings, change how costs are apportioned among manufacturers, alter the conditions under which EPA can demand testing, or modify the standards and timelines that drive those testing needs in the first place.
Direct Implications for Testing Costs
Testing costs arise in several TSCA contexts. Under Section 4, EPA can issue test orders requiring manufacturers or processors to generate hazard or exposure data; the associated fees and the laboratory costs of the studies themselves are borne by the companies. Under Section 5, new-chemical submitters must supply sufficient information for EPA to make a determination; inadequate data packages can trigger additional information requests or formal testing requirements, extending timelines and raising expense. Under Section 6, risk evaluations of existing chemicals can generate further data needs, and the manufacturers of those chemicals share both the EPA fee and any follow-on testing or risk-management compliance costs.
If reauthorization leaves the substantive data requirements unchanged but simply renews fee authority, companies will continue to face the current schedule of notification fees, evaluation fees and potential test-order costs. If reform packages succeed in narrowing the circumstances under which EPA can demand new testing, or in shifting more of the analytical burden onto EPA’s own resources, the private testing bill could decline—though possibly at the cost of longer or less predictable reviews if agency capacity is not increased. Conversely, any tightening of data expectations or expansion of the chemicals prioritized for evaluation would raise aggregate testing expenditure across the industry.
Cash-Flow and Planning Effects
Fee timing and magnitude already affect project economics. A $30,000-plus new-chemical fee is a noticeable line item for smaller innovators; a multi-million-dollar shared risk-evaluation fee can be material even for large portfolio companies. Uncertainty about whether fees will rise, fall, or be reallocated among more or fewer payers complicates multi-year R&D and product-stewardship budgeting. Companies with active new-chemical pipelines or with substances on EPA’s prioritization or evaluation lists have the greatest near-term exposure.
Small businesses benefit from reduced fee schedules under current rules. Any reform that preserves or expands those accommodations would protect one segment of the industry; any reform that narrows them would increase the relative cost of innovation for smaller players.
Outlook
The fight over TSCA fee authority is only partly about the fees themselves. It is also a proxy contest over the stringency, speed and data intensity of U.S. chemical regulation. A narrow reauthorization would maintain the existing cost structure for notifications, risk evaluations and testing. A broader legislative package could recalibrate those costs—either by changing fee formulas and allocation rules or by altering the underlying testing and review obligations that generate the expenses. Chemical manufacturers and importers should treat the December 2026 extension deadline as a planning horizon: monitor both the fee language and any accompanying substantive TSCA amendments, and stress-test product and testing budgets against scenarios in which compliance costs move materially higher or lower. In a regulatory system already characterized by high data demands and multi-year timelines, the next iteration of fee authority will help determine how expensive—and how predictable—those demands remain.
Sources
Mimosa Extract
Found this useful?
